The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are limited by small numbers and their single-center nature, and report conflicting data regarding predictors for response to IST. We examined outcomes associated with IST and predictors of benefit in a large international cohort of patients with MDS. Data were collected from 15 centers in the United States and Europe. Responses, including red blood cell (RBC) transfusion independence (TI), were assessed based on the 2006 MDS International Working Group criteria, and overall survival (OS) was estimated by Kaplan-Meier methods. Logistic regression models estimated odds for response and TI, and Cox Proportional Hazard models estimated hazards ratios for OS. We identified 207 patients with MDS receiving IST, excluding steroid monotherapy. The most common IST regimen was anti-thymocyte globulin (ATG) plus prednisone (43%). Overall response rate (ORR) was 48.8%, including 11.2% (95% confidence interval [CI], 6.5%-18.4%) who achieved a complete remission and 30% (95% CI, 22.3%-39.5%) who achieved RBC TI. Median OS was 47.4 months (95% CI, 37-72.3 months) and was longer for patients who achieved a response or TI. Achievement of RBC TI was associated with a hypocellular bone marrow (cellularity < 20%); horse ATG plus cyclosporine was more effective than rabbit ATG or ATG without cyclosporine. Age, transfusion dependence, presence of paroxysmal nocturnal hemoglobinuria or large granular lymphocyte clones, and HLA DR15 positivity did not predict response to IST. IST leads to objective responses in nearly half the selected patients with the highest rate of RBC TI achieved in patients with hypocellular bone marrows.

[1]  Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia. , 2018, The New England journal of medicine.

[2]  F. Bosch,et al.  Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes , 2018, Annals of Hematology.

[3]  A. Zeidan,et al.  Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications , 2017, Cancer.

[4]  A. Zeidan,et al.  Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends , 2017, Expert review of hematology.

[5]  G. Mufti,et al.  Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Lancet,et al.  Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. , 2016, Clinical lymphoma, myeloma & leukemia.

[7]  A. Stamatoullas,et al.  A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents , 2016, Haematologica.

[8]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[9]  Z. Estrov,et al.  Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium , 2015 .

[10]  R. Camire,et al.  Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity. , 2015, Blood.

[11]  J. Maciejewski,et al.  A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction , 2014, Haematologica.

[12]  L. Möllgård,et al.  Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial , 2014, Blood Cancer Journal.

[13]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[14]  P. Fenaux,et al.  How we treat lower-risk myelodysplastic syndromes. , 2013, Blood.

[15]  A. Barrett,et al.  Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. , 2012, Seminars in hematology.

[16]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[17]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[18]  A. Ganser,et al.  Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Storer,et al.  Anti‐thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study , 2010, British journal of haematology.

[20]  N. Young,et al.  Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Cella,et al.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). , 2009, Blood.

[22]  O. Shpilberg,et al.  ATG plus Cyclosporine Reduces All-Cause Mortality in Patients with Severe Aplastic Anemia – Systematic Review and Meta-Analysis , 2009, Acta Haematologica.

[23]  John Barrett,et al.  Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Gordon.  Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[25]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[26]  H. Kantarjian,et al.  A prognostic score for patients with lower risk myelodysplastic syndrome , 2008, Leukemia.

[27]  H. Mizoguchi,et al.  Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. , 2007, Blood.

[28]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Kurokawa,et al.  A Prospective Study of Cyclosporine A Treatment of Patients with Low-Risk Myelodysplastic Syndrome: Presence of CD55−CD59− Blood Cells Predicts Platelet Response , 2007, International journal of hematology.

[30]  G. Mufti,et al.  Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin , 2007, Leukemia.

[31]  B. Jiang,et al.  Treatment of Myelodysplastic Syndrome with Cyclosporin A , 2007, International journal of hematology.

[32]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[33]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[34]  B. Johansson,et al.  Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. , 2006, Haematologica.

[35]  H. Dombret,et al.  Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. , 2004, Blood.

[36]  H. Heimpel,et al.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.

[37]  A. Barrett,et al.  A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. , 2003, Blood.

[38]  A. Dispenzieri,et al.  Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. , 2003, Blood.

[39]  G. Mufti,et al.  A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‐risk’ myelodysplasia , 2003, British journal of haematology.

[40]  E. Estey,et al.  Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes , 2003, Leukemia.

[41]  N. Young,et al.  Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes , 2002, Annals of Internal Medicine.

[42]  S. Brunskill,et al.  Treatment of myelodysplasia with oral cyclosporin. , 2002, Clinical and laboratory haematology.

[43]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  D. Gilliland,et al.  Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome , 2000 .

[45]  M. Okada,et al.  Good response to cyclosporine therapy in patients with myelodysplastic syndrromes having the HLA-DRB1*1501 allele , 2000, Leukemia.

[46]  N. Piva,et al.  A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes , 1998, British journal of haematology.

[47]  J. Čermák,et al.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow , 1998, British journal of haematology.

[48]  N. Young,et al.  Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.

[49]  J. G. van den Tweel,et al.  Immunosuppressive therapy for hypoplastic myelodysplastic syndrome , 1997, Cancer.

[50]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[51]  P. A. Miescher,et al.  Autoimmune myelodysplasias. , 1991, Seminars in hematology.